Global Pediatric Vaccines Market Overview
Pediatric Vaccines Market Size was valued at USD 15.9 Billion in 2022. The Pediatric Vaccines market industry is projected to grow from USD 17.47 Billion in 2023 to USD 37.18 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 9.90% during the forecast period (2023 - 2032). Globally rising birthrates and an increase in the frequency of paediatric disorders are the key market drivers enhancing the market growth.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
It is not surprising that Sanofi has its eyes open on vaccine franchises despite the spotlight being taken by Dupixent. Pneumococcal disease, respiratory syncytial virus (RSV), flu, and some encouraging mRNA candidates are what can help boost this company's forecast, indicating billions of dollars before 2030. The biotech giant said it expected its immunizations to bring in over €10bn per year by 2030 during a recent R&D event for vaccines it hosted. Much of this growth is pinned on Sanofi's pipeline, where an "accelerated pace of innovation" targets at least five new phase three vaccine programs by 2025.
In September 2023, With the most popular data-sharing code set in the United States for medical services and procedures – Current Procedural Terminology (CPT®) 2024 code set – introduced consumer-friendly Spanish language descriptors. This translation service was just added to CPT's newly released consumer-friendly Spanish language descriptors for medical documents written in English by different hospitals, insurance companies, and healthcare providers such as those who sell price sheets through their patient portals…. Most healthcare facilities use easy-to-understand English-language descriptors approved under current procedural terminology guidelines, which provide an accessible guide to explaining various care processes to patients. Of course, clear and concise Spanish-language CPT labels will result in more helpful feedback from American doctors when they want to assist Latino clients.
In December 2023, Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) announced today that recruitment is now complete for the Phase III Vaccine Against Lyme for Outdoor Recreationists (VALOR) (NCT05477524) study evaluating investigational Lyme disease vaccine candidate VLA15. The trial builds on previous positive Phase 1 and 2 trial results and includes both adult and pediatric participants, with the aim to confirm the efficacy, safety, lot consistency, and immunogenicity of VLA15. Initiated in August 2022, the VALOR trial enrolled 9,437* participants five years of age and older from highly Lyme disease endemic areas in North America and Europe.
Pediatric Vaccines Market Trends
- Growing awareness is driving the market growth
Market CAGR for pediatric vaccines is being driven by the rising awareness. The market is expanding as a result of the rising incidence of chronic illnesses, including diphtheria, influenza, tetanus, pertussis, etc. The market is also growing since infectious and non-infectious illnesses in children are becoming more common. The Covid-19 epidemic also contributed to the market's rise as more people saw how crucial vaccinations are for protecting children from infections in the future. A chance for the market to expand exists due to the rise in vaccination approvals. The demand for vaccinations that need to be licensed rises with the frequency of infectious and chronic illnesses among children. Antigens (poly or oligosaccharides) are chemically bonded to the carrier protein in conjugate vaccinations. Polysaccharides become T-dependent antigens when the saccharides are attached to a protein, which causes both newborns and adults to have strong immunological reactions. These "glycoconjugate" vaccines cause B cells to create IgG antibodies against the conjugated polysaccharide with the assistance of T cells. According to the CDC, all children under the age of two should receive the pneumococcal conjugate vaccination (PCV13 or Prevnar13) regularly.Furthermore, the segment's growth is anticipated to be directly correlated with the increasing emphasis on research, government vaccination programs, expanding public awareness, as well as the efforts of corporations to advance vaccines
The main driver propelling market expansion is the rising frequency of different pediatric disorders and the rising number of births. Additionally, the market is expanding due to the growing need to enhance public health and the widespread use of pediatric vaccinations as a practical way to advance welfare internationally. Accordingly, creating effective and secure vaccines that remove and reduce harmful illnesses that transfer from child to child promotes market growth. A significant boost to the market's expansion is also provided by several product breakthroughs, such as the release of novel pediatric vaccinations that help treat adolescents and young children with relapsing forms of multiple sclerosis (RMS). Additionally, the market is growing due to the rising demand for combination vaccines that contain antigens, can induce immunological memory, and lower asymptomatic bacterial carriage. In addition, increasing government initiatives to support the accurate and timely administration of pediatric vaccinations, extensive research and development (R&D) activities, and growing awareness regarding early disease diagnosis and prevention are anticipated to propel the market even further toward growth. Thus, driving the Pediatric Vaccines market revenue.
Pediatric Vaccines Market Segment Insights
Pediatric Vaccines Type Insights
The Pediatric Vaccines market segmentation, based on type includes monovalent vaccines and multivalent vaccines. The monovalent vaccines segment dominated the market, accounting for 70% of market revenue due to their stability, safety, and capacity for an immediate immunological response. The frequency of infectious illnesses in children is on the rise, and leading companies are concentrating on producing hexavalent, tetravalent, and pentavalent vaccines. As a result, the multivalent vaccines sector is anticipated to have profitable growth throughout the projected period.
Figure 1: Pediatric Vaccines Market, by Type, 2022 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Pediatric Vaccines Technology Insights
The Pediatric Vaccines market segmentation, based on technology includes live attenuated, inactivated, subunits, toxoids, conjugates and others. The conjugates segment dominated the market. Due to their effectiveness in preventing a variety of human illnesses, these vaccinations are seen to be the most effective alternative to conventional immunisations. Additionally, the expansion of the subunit, recombinant, polysaccharide, and conjugate vaccine segments is anticipated to be aided by the rise in the number of regulatory approvals throughout the projection period. Additionally, a number of important actors have been actively studying polysaccharide vaccines in order to increase their recommended usage for the paediatric age range.
Pediatric Vaccines Application Insights
The Pediatric Vaccines market segmentation, based on Application, includes polio, diphtheria-tetanus-acellular pertussis, haemophilus influenzae type B, MMR, hepatitis B, pneumococcal vaccine and other. The pneumococcal vaccine category generated the most income (70.4%). Due to the development of new pneumococcal vaccinations for the paediatric vaccine market and an increase in patient knowledge of pneumococcal immunisations. Additionally, a number of government efforts, including different pneumococcal vaccination programmes, have aided in the market growth for pneumococcal vaccines. Additionally, the Action Plan for Pneumonia, a WHO project aimed at reducing pneumonia-related mortality, has fueled market expansion.
Pediatric Vaccines Regional Insights
By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American Pediatric Vaccines market area will dominate this market, the region's market for paediatric pharmaceuticals and vaccines is expanding as a result of factors like expanding treatment options for paediatric disorders, an established healthcare system, and high per capita healthcare spending.
Further, the major countries studied in the market report are The US, Canada, China, Japan, German, France, the UK, Italy, Spain, India, Australia, South Korea, and Brazil.
Figure 2: PEDIATRIC VACCINES MARKET SHARE BY REGION 2022 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe has the second-largest market share for Pediatric Vaccines. An increase in government funding for immunisation and the creation of paediatric vaccines, as well as an increase in R&D spending by several corporations. Furthermore, the German Pediatric Vaccines market dominated, while the UK Pediatric Vaccines market grew fastest in Europe.
From 2023 to 2032, the Asia-Pacific Pediatric Vaccines Market will develop at the quickest CAGR. Since there is a huge target population, major firms are focusing more on the Indian market for paediatric vaccines, and there are more government and non-government organisations promoting immunisation. Future growth of the market is predicted. Furthermore, China's Pediatric Vaccines market had the highest market share, whereas India's Pediatric Vaccines market was the Asia-Pacific region's fastest growing.
Pediatric Vaccines Key Market Players & Competitive Insights
Leading market companies are extensively spending R&D on increasing their product lines, which will help the Pediatric Vaccines market grow even more. Important market developments include new product releases, acquisitions and mergers, contractual agreements, greater investments, and collaboration with other organizations. The Pediatric Vaccines industry must produce cost-effective merchandise to flourish and thrive in a more competitive and increasing market climate.
Manufacturing locally to reduce operating costs is an effective business strategy manufacturers use in the worldwide Pediatric Vaccines industry to serve clients and expand the market sector. The Pediatric Vaccines industry has provided some of the most important benefits recently. VAXELIS, Colgate-Palmolive, and other major companies in the Pediatric Vaccines market are aiming to enhance market demand by investing in research and development activities.
The 1991 cooperation between Merck and Sanofi Pasteur in the United States led to the creation of VAXELIS, which is based on their combined expertise in the development, production, and marketing of both individual and combination vaccines. Diphtheria, tetanus, pertussis (whooping cough), and poliomyelitis antigens from Sanofi Pasteur and Haemophilus influenzae type b and hepatitis B antigens from Merck are both included in VAXELIS. The vaccine VAXELIS is recommended for active immunization to prevent invasive diseases caused by Haemophilus influenzae type b, diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and tetanus. Children 6 weeks to 4 years old (before their 5th birthday) may take VAXELIS in a 3-dose regimen. In June 2021, It is now possible to purchase VAXELIS in the United States because of a collaboration between Merck, known as MSD outside of North America and Canada, and Sanofi Pasteur, the company's worldwide vaccines business segment.
A British multinational pharmaceutical and biotechnology firm with its worldwide headquarters in London is GSK plc, an abbreviation for its previous name GlaxoSmithKline plc. Glaxo Wellcome and SmithKline Beecham merged to form this company in 2000. The business created the first malaria vaccine, RTS, and announced in 2014 that it would sell it for 5% more than the cost. Several legacy GSK medicines, including amoxicillin, mercaptopurine, pyrimethamine, and zidovudine, are included on the World Health Organization's List of Essential Medicines. In June 2022, The U.S. FDA has authorized Priorix for active immunization to prevent measles, mumps, and rubella (MMR) in people 12 months of age and older, according to a statement from GSK plc.
Key Companies in the Pediatric Vaccines market include
-
GlaxoSmithKline plc
-
Merck Sharp & Dohme Corp.
-
SANOFI
-
AstraZeneca
-
Pfizer, Inc.
-
Zydus Cadila
-
Indian Immunologicals Limited
-
Serum Institute of India Pvt. Ltd.
-
Mitsubishi Tanabe Pharma Corporatio
-
Panacea Biotec
-
Sinovac Biotech Ltd
-
Bio Med Pvt. Ltd.
Pediatric Vaccines Industry Developments
June 2022:The Food and Drug Administration gave the Pfizer-BioNTech COVID-19 vaccine emergency use authorization as a three-dose series for children aged 6 months to 4 years old.
August 2021:The pivotal PNEU-PED (V114-029) research, which recruited healthy babies between the ages of 42 and 90 days, evaluated the immunogenicity, safety, and tolerability of VAXNEUVANCE (Pneumococcal 15-valent Conjugate Vaccine). The licensed 13-valent pneumococcal conjugate vaccination (PCV13) or VAXNEUVANCE was administered to babies in the study in a 4-dose schedule at ages 2, 4, 6, and 12 to 15 months.
Pediatric Vaccines Market Segmentation
Pediatric Vaccines Type Outlook
-
Monovalent Vaccines
-
Multivalent Vaccines
Pediatric Vaccines Technology Outlook
-
Live Attenuated
-
Inactivated
-
Subunits
-
Toxoids
-
Conjugates
-
Others
Pediatric Vaccines Application Outlook
Pediatric Vaccines Regional Outlook
-
-
Germany
-
France
-
UK
-
Italy
-
Spain
-
Rest of Europe
-
Asia-Pacific
-
China
-
Japan
-
India
-
Australia
-
South Korea
-
Australia
-
Rest of Asia-Pacific
-
Rest of the World
-
Middle East
-
Africa
-
Latin America
| Report Attribute/Metric |
Details |
| Market Size 2022 |
USD 15.9 Billion |
| Market Size 2023 |
USD 17.47 Billion |
| Market Size 2032 |
USD 37.18 Billion |
| Compound Annual Growth Rate (CAGR) |
9.90% (2023-2032) |
| Base Year |
2022 |
| Market Forecast Period |
2023-2032 |
| Historical Data |
2018- 2022 |
| Market Forecast Units |
Value (USD Billion) |
| Report Coverage |
Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered |
Type, Application, and Region |
| Geographies Covered |
North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered |
The US, Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled |
Sanofi S.A., GlaxoSmithKline plc, Merck & Co., Inc., Pfizer Inc., Grifols, Serum Institute of India Pvt. Ltd., AstraZeneca, Cadila Healthcare Ltd, Indian Immunologicals Limited, and CSL Limited. |
| Key Market Opportunities |
New product launches and R&D Amongst major |
| Key Market Dynamics |
Increasing awareness regarding the benefits of vaccination |
Frequently Asked Questions (FAQ) :
The Pediatric Vaccines market size was valued at USD 15.9 Billion in 2022.
The market is projected to grow at a CAGR of 9.90% during the forecast period, 2023-2032.
North America had the largest share in the market
The key players in the market are Sanofi S.A., GlaxoSmithKline plc, Merck & Co., Inc., Pfizer Inc..
The Monovalent Vaccines dominated the market in 2022.
The Pneumococcal Vaccine had the largest share in the market.
